NFTs (neurofibrillary tangles) in Alzheimer's disease and in tauopathies are hallmark neuropathological lesions whose relationship with neuronal dysfunction, neuronal death and with other lesions [such as Aβ (amyloid β-peptide) pathology] are still imperfectly understood. Many transgenic mice overexpressing wild-type or mutant tau proteins have been generated to investigate the physiopathology of tauopathies. Most of the mice overexpressing wild-type tau do not develop NFTs, but can develop a severe axonopathy, whereas overexpression of mutant tau leads to NFT formation, synaptic loss and neuronal death in several models. The association between neuronal death and NFTs has, however, been challenged in some models showing a dissociation between tau aggregation and tau toxicity. Cross-breeding of mice developing NFTs with mice developing Aβ deposits increases NFT pathology, highlighting the relationship between tau and amyloid pathology. On the other hand, tau expression seems to be necessary for expression of a pathological phenotype associated with amyloid pathology. These findings suggest that there is a bilateral cross-talk between Aβ and tau pathology. These observations are discussed by the presentation of some relevant models developed recently.
Introduction
AD (Alzheimer's disease) is neuropathologically characterized by the presence of NFTs (neurofibrillary tangles) and SPs (senile plaques) [1] , and the distribution and the abundance of these brain lesions are used as neuropathological criteria for the diagnosis of AD [2, 3] . NFTs are made of bundles of PHFs (paired helical filaments) composed of abnormally and hyperphosphorylated aggregated forms of the microtubuleassociated protein tau [4] . SPs are made of an extracellular core of the Aβ (amyloid β-peptide) peptide, deriving by proteolysis from the APP (amyloid precursor protein), surrounded by dystrophic neurites and reactive glial cells. The mechanisms of formation of these lesions, their interrelationship and their effects on brain function are still matters of debate. According to the amyloid cascade hypothesis, Aβ exerts a toxic effect, inducing the tau pathology [5] . Many clinicopathological studies have, however, demonstrated a closer correlation between the number of NFTs with the severity of dementia than with SPs in patients with AD [6] , suggesting that NFTs exert a toxic effect or at least act as a witness for the presence of a physiopathological mechanism related to abnormal tau processing [7, 8] . The availability of transgenic models expressing wild-type or mutant forms of APP, PS (presenilin) 1 and 2 and tau (identified in familial forms of AD and frontotemporal dementia) has made it possible to investigate these mechanisms experimentally in animal models [9] . The present review is devoted to the
Neuronal death, tau toxicity and tau aggregation
The relationship between neuronal death and NFT formation has long been debated, but is still not yet settled. Neuronal loss in AD is correlated with NFT load in the hippocampus and the cortex [10] , but exceeds NFT accumulation [11] . Although both NFT and SP distribution and abundance are used as neuropathological criteria for the diagnosis of AD [2, 3] , the relationship between these brain lesions and dementia weakens with age [12] .
The complexity of the association between NFTs and neuronal dysfunction/death has, to some extent, also been observed in transgenic models (e.g. see [8] ). Transgenic models overexpressing mutant tau almost systematically develop NFTs and behavioural deficits [13, 14] . Tau aggregation has been observed to enhance synaptic loss in tau transgenic mice [15] . Neuronal loss is present to varying degrees in these models, and is sometimes temporally or spatially dissociated from NFT accumulation [16] . In a transgenic model overexpressing P301L tau in a conditional manner, switching off mutant tau expression at 4 months improved a behavioural phenotype and reduced neuronal cell death, but in the absence of a decrease in NFTs [17] . In the same model, NFT-bearing neurons showed caspase activation, but without evolution towards acute neuronal death [18] . We have developed a transgenic mouse line (Tg30tau) overexpressing a G272V/P301S mutant tau in the brain and the spinal cord [19] . Tg30tau mice develop numerous NFTs in the cortex, the hippocampus and the spinal cord, and a motor deficit. Stereological analysis of neuron number in the hippocampus (sectors CA1-CA4) or neuron density in the cervical spinal cord did not, however, identify a neuronal loss in Tg30tau mice. Recently, we investigated the potential effect of lithium treatment, as an inhibitor of GSK3β (glycogen synthase kinase 3β), on tau phosphorylation and tau aggregation in these Tg30tau mice [20] . As in other studies, we observed that acute lithium treatment was effective in reducing tau phosphorylation. Lithium treatment also decreased the amount of sarkosyl-insoluble aggregated tau and arrested the formation of NFTs in the hippocampus and the spinal cord ( Figure 1 ). However, the motor deficits were not different between lithium-and sodium-treated Tg30tau mice, suggesting that NFT load could be dissociated from a motor phenotype in these lithium-treated mice. Alternatively, the absence of reversal of NFT formation in a model with severe neurofibrillary pathology might render difficult the rescue of an end-stage motor phenotype. We recently generated a transgenic line overexpressing G272V/P301S mutant tau in absence of murine tau (see the paper by Ando et al. [20a] on pp. 1001-1005 of this issue of Biochemical Society Transactions for details). These mice develop a more severe neurofibrillary pathology and a more severe motor phenotype, but in the absence of apparent increased neuronal cell death.
These observations do not exclude a toxic effect of NFTs as a contributing pathological mechanism in AD and other tauopathies. Nevertheless, they indicate that tau aggregation can be dissociated from neuronal death or dysfunction in several models. Other molecular species or lesions could be responsible for the latter effects. Abnormally conformed and phosphorylated tau is toxic in Drosophila models, in the absence of NFT formation [21] , although co-expression of GSK3β induces neurofibrillary pathology and exacerbates neurodegeneration [22] . Abnormally hyperphosphorylated tau in AD has toxic functions [23] . Pseudophosphorylated tau is toxic in cultured cells in absence of aggregation [24] . Tau oligomers have been identified in some transgenic models [25] and might mediate a toxic effect in neurons, and spreading of tau pathology from cell to cell [26] . Tau aggregation itself has been suggested to play a protective role by sequestering toxic tau species. Synaptic loss [27] , and/or atrophy of dendritic trees might prove to be more powerful indicators of neuronal functions than neuronal death and NFTs in these transgenic models, as already suggested in AD.
Relationship between Aβ and tau pathologies
One of the key questions of AD physiopathology is the mechanistic relationship between Aβ and tau pathology [28, 29] .
There is no doubt that abnormal APP and tau processing can, independently, lead to neurodegeneration. According to the amyloid cascade hypothesis, amyloid formation precedes and causes tau pathology. At least in the initial state, there is, however, a spatial and a temporal dissociation between tau and Aβ pathologies [2] . Some transgenic models offer opportunities to investigate the mechanistic relationships between the formation of Aβ and tau lesions. Transgenic mice expressing human wild-type or mutant APP, or both APP and PS1 mutants, do not develop NFTs, an unexpected observation in the framework of the amyloid cascade. Transgenic mice expressing mutant PS1 and wild-type human tau [30] , or both mutant APP and PS1, in the presence of wildtype human tau [31] do not develop NFTs either. Many of the models developing both amyloid plaques and NFTs thus rely on the expression of both mutant APP and tau proteins. In an initial study, transgenic mice expressing a P301L mutant tau were crossed with transgenic mice expressing the APPsw mutation, to generate double mutants developing both Aβ deposits and NFTs [32] . Interestingly, these double mutants exhibited an enhanced neurofibrillary pathology, suggesting that APP and/or Aβ fostered NFT formation. This enhancement of tau pathology in transgenic mice developing Aβ deposits has been confirmed in several models [33] [34] [35] .
In addition, in a triple-transgenic model expressing the mutant APPsw, M146VPS1 and P301Ltau (3 × Tg-AD), intraneuronal Aβ [and concomitant LTP (long-term potentiation) deficits] accumulated before extracellular Aβ, which itself developed before NFTs [36] . In this 3 × Tg-AD model, clearance of Aβ by immunotherapy also led to clearance of tau pathology, suggesting that Aβ was upstream of tau pathology [37] . This hypothesis is sustained further by the observation that injection of Aβ42 fibrils into the brains of P301L mutant tau transgenic mice also enhanced formation of NFTs [38] . Infusion of brain extracts of aged APP mice (APP23) in P301L mice similarly induced tau pathology, even at a distance [34] .
The inverse hypothesis (i.e. that tau pathology could induce SPs) is not sustained by studies in frontotemporal dementia or in transgenic animals (transgenic mice expressing mutant tau proteins do not develop amyloid deposits). Although these results sustain the concept of the amyloid cascade, several studies have investigated the possibility of a reverse effect, i.e. that tau pathology could influence the development of the amyloid pathology. For instance, an enhancement of amyloid deposition was observed in double-transgenic mice expressing the mutants APPsw and tau [39] . In another transgenic model, an increase in tau levels, however, had no effect on the onset and progression of amyloid pathology [40] .
We recently reassessed the relationship between amyloid and tau pathology by crossing transgenic mice expressing three APP mutations and two PS1 mutations (5 × FAD mice) [41] with Tg30tau transgenic mice [19] . The phenotype of the resulting double 5 × FAD/Tgtau30 transgenic mice was compared with those of the single APP and tau mice. These double-mutant mice developed both a severe amyloid and tau pathology as did the original single APP and tau transgenic mice, as expected. At 9 and 12 months, the NFT load in the hippocampus and the cortex was increased considerably in 5 × FAD/Tgtau30 mice, confirming that mutant APP, PS1 and/or Aβ fostered NFT formation (Figure 2 ). 5 × FAD/Tgtau30 mice had a more severe motor deficit than Tgtau30 mice, correlated with an increased density of NFTs in the spinal cord.
Thus, altogether, these transgenic models sustain the amyloid cascade in the sense that overexpression of mutant APP, alone or in combination with mutant PS1 accelerates NFT formation, but extracellular Aβ by itself is not correlated with memory deficits, as observed in many APP models [42] . Other Aβ molecular species, such as soluble oligomeric Aβ*, might be responsible for the phenotypic defects observed in these models. It should be pointed that these transgenic models do not yet prove completely the amyloid cascade (as expected for 'sporadic' cases of AD, without any APP mutations), i.e. that Aβ causes NFT formation, since the expression of a mutant tau protein (that by itself induces the formation of NFTs) is needed to observe the accelerating effect of APP/PS1 on NFT formation. The emerging concept is, however, one of a synergistic relationship between APP/Aβ and tau, and several mechanisms have been proposed to explain this synergizing effect between Aβ and tau, e.g. Aβ inhibition of proteasome [43] , increased Cdk5 (cyclin-dependent kinase 5) or GSK3β activity [35] or caspase activation [44] .
Pathological phenotypes in APP transgenic mice need tau expression
Although much of the current results sustain a one-way mechanism in which APP/Aβ is the primary event causing neuronal dysfunction, several intriguing results suggest that tau and tau pathology might also influence the development and the expression of amyloid pathology. For instance, many studies indicated that Aβ added to culture medium had a toxic effect on cultured neurons expressing tau; however, cultured neurons with a knockout tau gene were resistant to Aβ toxicity [45] . Transgenic mice overexpressing a mutant APP and presenting behavioural deficits were crossed with tauknockout mice; the absence of tau prevented the development of these behavioural deficits in the resulting APP/tauKO mice, without affecting the level of Aβ [46] . To investigate further this relationship, we have crossed transgenic mice expressing both mutant APP and PS1 (5 × FAD mice) with mice bearing an inactivated tau gene [47] . The resulting mice 5 × FAD/tauKO thus express mutant APP and PS1 in the absence of tau. These 5 × FAD/tauKO mice develop similar loads of Aβ deposits in the hippocampus as the single 5 × FAD mice (Figure 3) . Although the single 5 × FAD mice developed a spatial memory deficit at 12 months, this deficit was rescued in 5 × FAD/tauKO mice. A stereological analysis of neuron number in the hippocampus showed a weak, but significant, neuronal loss in 5 × FAD mice at 12 months that was absent from 5 × FAD/tauKO mice. Thus our results indicate that tau inactivation rescued memory deficits in APP/PS1 mice as reported previously in APP mice, but also rescued neuronal cell death in these APP/PS1 mice. The mechanisms underlying this intriguing rescue will need to be deciphered, but it seems that some biological function of tau is needed to induce neuronal dysfunction/death associated with mutant APP/Aβ expression or processing. 
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